1. Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study.
- Author
-
Henderson JJ, Das A, Morgenstern DA, Sudhaman S, Bianchi V, Chung J, Negm L, Edwards M, Kram DE, Osborn M, Hawkins C, Bouffet E, Cho YJ, and Tabori U
- Subjects
- Humans, Immunotherapy, Immune Checkpoint Inhibitors pharmacology, Neoplasms drug therapy
- Abstract
Competing Interests: Daniel A. MorgensternHonoraria: Ology Medical Education, WebMD, PlatformQ HealthConsulting or Advisory Role: Clarity Pharmaceuticals, EUSA Pharma, Ymabs Therapeutics IncSpeakers' Bureau: Ymabs Therapeutics IncResearch Funding: Bristol Myers Squibb (Inst), AbbVie (Inst), Lilly (Inst), Bayer (Inst), Cellectar (Inst), Roche (Inst)Travel, Accommodations, Expenses: Lilly Sumedha SudhamanEmployment: Strand Life Sciences David E. KramConsulting or Advisory Role: Foundation Medicine Cynthia HawkinsConsulting or Advisory Role: BayerPatents, Royalties, Other Intellectual Property: IP for low-grade glioma and sarcoma fusion panels as well as medulloblastoma subgrouping panel Eric BouffetConsulting or Advisory Role: NovartisResearch Funding: Roche (Inst), Bristol Myers Squibb (Inst) Yoon-Jae ChoExpert Testimony: Barr and MudfordNo other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF